Data −Apr 17, 2026
Negative data — 3 Reasons A is Risky and 1 Stock to Buy Instead▸
high impact
ApprovalMar 27, 2026
FDA approval — Agilent receives FDA approval for PD-L1 1HC 22C3 pharmDx▸
high impact
ApprovalMar 26, 2026
FDA approval — Agilent Technologies Receives FDA Approval For PD-L1 IHC 22C3 PharmDx Code SK006 As Companion Diagnostic To Aid In Iden…▸
high impact
DealMar 24, 2026
Deal — Agilent Technologies (A) to Acquire Biocare Medical for $950M▸
medium impact
DealMar 13, 2026
Deal — Deal Dispatch: Papa John's May Go Private, Shell Buys Jiffy Lube, Meta Acquires Moltbook▸
medium impact
DealMar 10, 2026
Deal — Agilent Bets On Pathology Innovation With Biocare Acquisition▸
medium impact
DealMar 09, 2026
Deal — Agilent to Acquire Biocare Medical in $950 Million All-Cash Deal▸
medium impact
EarningsFeb 25, 2026
Q1 2026 report-5.3%negative
ApprovalFeb 11, 2026
FDA approval — Agilent Technologies Says FDA Approves PD-L1 IHC 22C3 pharmDx In Identifying First-Line Patients With Epithelial Ovaria…▸
high impact
EarningsNov 24, 2025
FY 2025 report-0.1%muted
EarningsAug 27, 2025
Q3 2025 report+5.5%positive
EarningsMay 28, 2025
Q2 2025 report+0.2%muted
EarningsFeb 26, 2025
Q1 2025 report-6.0%negative
EarningsNov 25, 2024
FY 2024 report+2.6%muted
EarningsAug 21, 2024
Q3 2024 report+0.4%muted
EarningsMay 29, 2024
Q2 2024 report-9.7%negative